Navigating the ever-increasing complexity of Market Access in Europe demands a lot from pharmaceutical providers. Staying on top of changes in the legislative system, considering uncertainties such as label assumptions and their implications for the launches as well as meeting rising demands from HTA authorities for evidence creates sophisticated challenges for successful European commercialization of pharmaceutical products.
IGES with its vast experience in the realm of Market access can support your product from cutting through the complexity to find the right route of access via mapping out the necessary steps required to achieve your goal until the implementation of the required activities. Since IGES supports operationally along the whole Market Access process chain, we know what matters when deciding for scenarios and planning your activities.
Analysis of most suitable pricing strategy by considering product characteristics, current standard of care and future competition. Data driven modelling and insights through its network of current and ex-payers allow for estimation of realistic price assumptions tailored to product properties. Early predictions will cover different scenarios to account for uncertainites in assumptions (e.g. exact indication).
Quantification of the commercial potential of a drug compound in development in Europe. Factors to consider revolve around the epidemiology of the disease, most likely HTA assessment in respective countries, the competitive situation and possible reference prices.
Identification of relevant competitors with the same or similar active ingredients/therapeutic approaches. In addition, analysis of the competitor's planned pipeline products. Analysis of the implications and possible threats for the respective product.
Analysis of product and indication specific reimbursement pathways with consideration of special options for innovative medicines to drive commercial success. Pathways need to consider care setting of eligible patients as an integrated concept accounting for specific characteristics of the outpatient and inpatient sector.
Strategic support in internal development of a business case by validating assumptions to facilitate informed decision-making. Operational support in conceptualization, development and programming of business case models possible.